BFEC
BLCM

Benjamin F. Edwards & Company’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Benjamin F. Edwards & Company’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-20
Closed -$2K – 1703
2017
Q4 		$2K Hold
20
– – ﹤0.01% 1510
2017
Q3 		$2K Sell
20
-10
-33% -$1.05K ﹤0.01% 1470
2017
Q2 		$4K Sell
30
-10
-25% -$1.24K ﹤0.01% 1294
2017
Q1 		$5K Sell
40
-10
-20% -$1.31K ﹤0.01% 1172
2016
Q4 		$7K Hold
50
– – ﹤0.01% 1019
2016
Q3 		$10K Buy
+50
New +$8.61K ﹤0.01% 858

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Benjamin F. Edwards & Company's BLCM Position: Q1 2018 in Review

Benjamin F. Edwards & Company sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2018, closing a stake of 20 shares — an estimated $2K sold.

Benjamin F. Edwards & Company first reported a position in BLCM in Q3 2016 and held it in 6 quarters. The position peaked at $10K in Q3 2016. 90 funds tracked by Wall St. Rank hold BLCM as of Q1 2018.

  • Benjamin F. Edwards & Company reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 20 Bellicum Pharmaceuticals, Inc. shares in Q1 2018, an estimated $2K.
  • Benjamin F. Edwards & Company first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2016 and held it in 6 quarters.
  • Benjamin F. Edwards & Company's Bellicum Pharmaceuticals, Inc. position peaked at $10K in Q3 2016.
  • 90 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2018.

Based on Benjamin F. Edwards & Company's 13F filing for Q1 2018, filed 17 Apr 2018.